Johnson & Johnson Seeks FDA Approval for First-Ever Treatment of Rare Blood Disorder wAIHA
核心洞察
Johnson & Johnson submitted a supplemental Biologics License Application to the FDA seeking approval of IMAAVY (nipocalimab-aahu (搜索)) as the first-ever treatment for warm autoimmune hemolytic anemia (搜索) (wAIHA (搜索)), a rare disease affecting 1 in 8,000 Americans.
The Phase 2/3 ENERGY trial demonstrated that more patients treated with nipocalimab achieved durable hemoglobin response compared to placebo, with improvements in both anemia (搜索) and fatigue symptoms.
wAIHA (搜索) patients currently have no FDA-approved treatment options and face a 20-30% higher risk of death, making this potential approval a significant milestone for the rare disease community.
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration seeking approval of IMAAVY (nipocalimab-aahu (搜索)) as the first-ever treatment for patients with warm autoimmune hemolytic anemia (搜索) (wAIHA (搜索)). This rare and serious autoantibody disease affects approximately 1 in 8,000 people in the United States and currently has no approved treatments despite substantial unmet medical need.
The condition is associated with significant morbidity and mortality, with patients experiencing a 20-30% higher risk of death compared to the general population. wAIHA (搜索) occurs when harmful immunoglobulin G (IgG) autoantibodies attach to and destroy red blood cells, leading to anemia (搜索) and serious complications including profound chronic fatigue, transfusion dependence, and organ failure.
"People living with warm autoimmune hemolytic anemia (搜索) face a serious, life-threatening disease with no approved treatment options and a high risk of complications," said David M Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head at Johnson & Johnson. "The submission of this sBLA represents an important milestone for the wAIHA (搜索) community and underscores our commitment to advancing targeted, immunoselective therapies that can deliver meaningful, rapid improvement for these patients."
Mechanism of Action and Clinical Evidence
IMAAVY is designed to selectively block the neonatal Fc receptor (搜索) (FcRn (搜索)), a key regulator of IgG recycling. By reducing circulating IgG, including autoantibodies, IMAAVY targets the underlying cause of disease while preserving critical immune functions, including some humoral B-cell responses to new infections.
The sBLA submission is supported by data from the Phase 2/3 ENERGY multicenter, randomized, double-blind, placebo-controlled study evaluating IMAAVY in adults living with wAIHA (搜索). The trial demonstrated that more patients treated with nipocalimab achieved the stringent primary endpoint of a durable hemoglobin response compared with placebo. A durable response was defined as achieving a hemoglobin level above 10 g/dL and an increase of at least 2 g/dL for at least 28 days, without the need for rescue therapy.
Beyond hemoglobin improvements, more patients treated with IMAAVY experienced rapid and sustained improvement in fatigue as assessed by FACIT-Fatigue, an outcome of significant importance to people living with wAIHA (搜索).
"The ENERGY study demonstrated clinically meaningful results in adults living with warm autoimmune hemolytic anemia (搜索)," said Bruno Fattizzo, M.D., Assistant Professor at the Department of Oncology and Hematology-Oncology, Università degli Studi di Milano. "These results provide a strong rationale for the potential of IMAAVY to rapidly improve fatigue and provide durable hemoglobin response while maintaining favorable tolerability."
Safety Profile and Current Approvals
IMAAVY was generally well tolerated in the ENERGY trial, with no new safety signals identified and a safety profile consistent with the existing IMAAVY label. The drug was approved in the United States in April 2025 for the treatment of generalized myasthenia gravis (搜索) (gMG (搜索)) in adult and pediatric patients 12 years of age and older who are acetylcholine receptor (搜索) (AChR (搜索)) or muscle-specific kinase (搜索) (MuSK (搜索)) antibody positive.
Disease Background and Unmet Need
Warm autoimmune hemolytic anemia (搜索) is a rare, life-threatening condition affecting approximately 1-3 new people per 100,000 annually. The condition affects both women and men and can occur at any age, with incidence increasing over age 50. Patients with wAIHA (搜索) face increased risk of serious complications including venous thrombotic events, acute renal failure, and infection.
Currently, no FDA-approved drugs are indicated for wAIHA (搜索), and treatment typically consists of unapproved corticosteroids, broad immunosuppressants, and B-cell directed therapies. The lack of approved treatments represents a critical unmet medical need for this patient population.
Regulatory Recognition
Nipocalimab has received multiple regulatory designations recognizing its potential therapeutic value. The FDA has granted Fast Track designation for wAIHA (搜索) in July 2019 and Orphan drug status in December 2019. The drug is also being investigated across multiple autoantibody-mediated conditions, including rheumatologic diseases, rare autoantibody diseases, and maternal fetal diseases.